---
schema_version: "secwatch.filing_event.v1"
accession: "0000950130-25-000140"
form_type: "8-K"
ticker: "CUE"
cik: "0001645460"
company_name: "Cue Biopharma, Inc."
filed_at: "2025-09-29T23:59:59+00:00"
generated_at: "2026-05-17T05:24:31.463591+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cue Biopharma appoints Usman Azam as CEO, succeeding Daniel Passeri who transitions to advisor

## Summary
- Usman Azam appointed President and CEO effective Sept 29, 2025; succeeds Daniel Passeri who retires and becomes strategic advisor.
- Azam receives base salary $620,000, bonus target 50% of base, stock options for 2.25M shares (1.875M time-based + 375K performance-based).
- Passeri receives lump sum severance of $838,750, 12-month equity vesting acceleration, and COBRA for 18 months.
- Passeri advisor agreement: stock option for 375K shares tied to financing milestone, term through March 30, 2026, with continued equity vesting.

## SEC filing metadata
- accession: 0000950130-25-000140
- form_type: 8-K
- ticker: CUE
- cik: 0001645460
- company_name: Cue Biopharma, Inc.
- filed_at: 2025-09-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645460/000095013025000140/0000950130-25-000140-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645460/000095013025000140/cue-20250926.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950130-25-000140
- JSON: https://secwatch.observer/filing/0000950130-25-000140.json
- Plain text: https://secwatch.observer/filing/0000950130-25-000140.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.